Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DYAI 
Dyadic International Inc (DYAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: DYAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.3% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.75M USD | Price to earnings Ratio - | 1Y Target Price 5.67 |
Price to earnings Ratio - | 1Y Target Price 5.67 | ||
Volume (30-day avg) 1 | Beta 1.22 | 52 Weeks Range 0.71 - 2.20 | Updated Date 11/13/2025 |
52 Weeks Range 0.71 - 2.20 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When After Market | Estimate -0.04 | Actual -0.06 |
Profitability
Profit Margin -134.84% | Operating Margin (TTM) -177.21% |
Management Effectiveness
Return on Assets (TTM) -36.14% | Return on Equity (TTM) -422.64% |
Valuation
Trailing PE - | Forward PE 15.82 | Enterprise Value 30228790 | Price to Sales(TTM) 10.83 |
Enterprise Value 30228790 | Price to Sales(TTM) 10.83 | ||
Enterprise Value to Revenue 16.66 | Enterprise Value to EBITDA -2.93 | Shares Outstanding 36187798 | Shares Floating 26907437 |
Shares Outstanding 36187798 | Shares Floating 26907437 | ||
Percent Insiders 25.17 | Percent Institutions 11.39 |
Upturn AI SWOT
Dyadic International Inc
Company Overview
History and Background
Dyadic International Inc. was founded in 1979. Initially involved in diagnostic testing, it transitioned to biotechnology focusing on the development and commercialization of its patented C1 technology platform, a fungal expression system.
Core Business Areas
- C1 Technology Platform: Dyadic's primary business revolves around the C1 fungal expression system. This platform is used to develop and manufacture enzymes and other proteins for various industries including human and animal health, and industrial applications.
- Licensing and Collaborations: Dyadic generates revenue through licensing agreements and collaborations with companies seeking to utilize the C1 platform for their protein production needs. This also includes technology transfer and support services.
Leadership and Structure
Mark Emalfarb is the Founder and CEO. The company has a board of directors responsible for oversight and strategic direction. The organizational structure is functionally organized, with departments for research & development, manufacturing, licensing, and finance.
Top Products and Market Share
Key Offerings
- C1 Technology Platform for Enzyme Production: The C1 platform allows for efficient and cost-effective production of a wide range of enzymes, used in biofuels, animal feed, food processing, and other industrial applications. Precise market share data is not publicly available, but Dyadic competes with companies offering other expression systems like yeast-based systems and bacterial fermentation. Competitors include Novozymes (Denmark) and DSM (Netherlands).
- C1 Technology Platform for Pharmaceutical Protein Production: C1 is being developed for the production of pharmaceutical proteins including vaccines, antibodies, and other therapeutic proteins. Competition includes mammalian cell culture systems offered by companies like Lonza (Switzerland) and Thermo Fisher Scientific (US).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation and intense competition. Demand for efficient protein production systems is driven by the growing need for enzymes in various sectors and increasing demand for biologics in human and animal health.
Positioning
Dyadic positions itself as a provider of a cost-effective and scalable alternative to traditional expression systems. The C1 platform's robustness and potential for high yields are key competitive advantages.
Total Addressable Market (TAM)
The global market for biopharmaceutical manufacturing is expected to reach hundreds of billions of dollars. The enzyme market is estimated to be in the tens of billions. Dyadic is positioned to capture a segment of these markets by offering a competitive production platform.
Upturn SWOT Analysis
Strengths
- Proprietary C1 Technology Platform
- Potential for high protein yields
- Cost-effective production
- Scalable technology
- Partnerships with established companies
Weaknesses
- Limited commercialized products
- Dependence on licensing agreements
- Reliance on partner success
- Relatively small company size
- Fluctuations in revenue stream
Opportunities
- Expanding into new applications (e.g., vaccines, biologics)
- Increasing demand for biosimilars
- Growing interest in sustainable biomanufacturing
- Strategic partnerships with larger pharmaceutical companies
- Geographic expansion
Threats
- Competition from established expression systems
- Regulatory hurdles
- Patent infringement risks
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- NOVO
- DSM
- LNZAY
- TMO
Competitive Landscape
Dyadic's competitive advantage lies in its proprietary C1 platform's cost-effectiveness and scalability, particularly for certain enzyme and protein production applications. However, it faces strong competition from larger companies with established market presence and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on licensing agreements and milestones achieved in partnerships.
Future Projections: Future projections depend on the success of the C1 platform in different applications and the ability to secure new partnerships. Analyst estimates can provide insights, but are subject to change.
Recent Initiatives: Recent initiatives include expanding the C1 platform for vaccine production and pursuing partnerships in the pharmaceutical sector.
Summary
Dyadic International is a biotechnology company leveraging its C1 technology for cost-effective protein production. The company's strength lies in its proprietary platform and strategic partnerships. However, it needs to enhance its product portfolio and navigate intense competition. Recent initiatives in vaccines and biologics show promise but are subject to development risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Investor Presentations
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise. Financial information is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyadic International Inc
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2004-11-05 | Founder, CEO & Director Mr. Mark A. Emalfarb | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.dyadic.com |
Full time employees 6 | Website https://www.dyadic.com | ||
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.